Зміни лабораторних показників та функціонального стану лівого шлуночка у чоловіків з надлишковою масою тіла та ожирінням залежно від важкості хронічної серцевої недостатності
DOI :
https://doi.org/10.15587/2313-8416.2016.61222Mots-clés :
серцева недостатність, важкість, чоловіки, ожиріння, лабораторна діагностика, функціональний стан міокардаRésumé
Досліджено зімни лабораторних показників та функціонального стану лівого шлуночка (ЛШ) у чоловіків з надлишковою масою тіла та ожирінням залежно від важкості хронічної серцевої недостатності (ХСН). З підвищенням ФК ХСН існує схильність до анемізації, формування ниркової дисфункції та кардіогенного ураження печінки, поширюється систолічна, діастолічна дисфункція ЛШ та легенева гіпертензія
Références
Acuna, C. (2014). Prolonhirovannaia forma torasemida: chto novoho? [Prolonged form of torasemid: what new?]. Heart failure, 3, 33–39.
Parkhomenko, A. N. (2014). Problema serdechnoi nedostatochnosti kak vyzov sovremennomu obshestvu [The problem of heart failure as a challenge to modern society]. Heart failure, 3, 6–10.
Voronkov, L. H. et. al (2013). Rekomendacii po diahnostike I lecheniu khronicheskoi serdechnoi nedostatochnosti (2012) [Guidelines for the diagnosis and treatment of chronic heart failure (2012)]. Ukrainian cardiology journal, 1, 6–44.
Westenbrink, B. D., Voors, A. A., de Boer, R. A., Schuringa, J. J., Klinkenberg, T., van der Harst, P. et. al (2010). Bone marrow dysfunction in chronic heart failure patients. European Journal of Heart Failure, 12 (7), 676–684. doi: 10.1093/eurjhf/hfq061
Allen, L. A., Felker, G. M., Pocock, S., McMurray, J. J. V., Pfeffer, M. A., Swedberg, K. et. al (2009). Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 11 (2), 170–177. doi: 10.1093/eurjhf/hfn031
Voronkov, L. H. (2015). Anemia u patsienta s KHSN: kak otsenivat I kak lechit? [Anemia in patients with CHF: how to evaluate and how to treat?]. Heart failure, 2, 5–14.
Karakas, M. S., Korucuk, N., Tosun, V., Altekin, R. E., Koç, F., Ozbek, S. C. et. al (2015). Red cell distribution width and neutrophil-to-lymphocyte ratio predict left ventricular dysfunction in acute anterior ST-segment elevation myocardial infarction. Journal of the Saudi Heart Association. doi: 10.1016/j.jsha.2015.07.001
Testani, J. M., Kimmel, S. E., Dries, D. L., Coca, S. G. (2011). Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction. Circulation: Heart Failure, 4 (6), 685–691. doi: 10.1161/circheartfailure.111.963256
Damman, K., Voors, A. A., Hillege, H. L., Navis, G., Lechat, P., van Veldhuisen, D. J., Dargie, H. J. (2010). Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. European Journal of Heart Failure, 12 (9), 974–982. doi: 10.1093/eurjhf/hfq118
Szyguła-Jurkiewicz, B., Wojnicz, R., Lekstron, A. et. al (2007). Effect of elevated bilirubin levels on the long-term outcome in patients with chronic heart failure due to hypertension. Pol. Arch. Med. Wewn., 117, 227–233.
Poelzl, G., Ess, M., Mussner-Seeber, C., Pachinger, O., Frick, M., Ulmer, H. (2011). Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. European Journal of Clinical Investigation, 42 (2), 153–163. doi: 10.1111/j.1365-2362.2011.02573.x
Branca, F., Nikogosian, H., Lobstein, T. (Eds.) (2007). The challenge of obesity in the WHO European Region and the strategies for response: summary. World Health Organization, 77.
Horbas, I. M. (2007). Faktory ryzyku sertsevo-sudynnykh zakhvoriuvan: poshirennist I control [Risk factors for cardiovascular disease: prevalence and control]. Health of Ukraine, 21 (1), 62–63.
Dub, M., Meleha, K. (2012). Suchasni pidhody do fizychnoi reabilitatsii osib z nadlyshkovoiu massoiu tila ta ozhirinniam [Modern approaches to physical rehabilitation of persons with overweight and obesity]. Young sportive science of Ukraine, 3, 87–94.
Berezin, A. E., Samura, T. A. (2013). Galektin-3 kak phenotipicheskiy indicator kardiovaskuliarnoho riska u patsientiv s serdechnoy nedostatochnostiu [The galectin-3 as a phenotypic indicator of cardiovascular risk in patients with heart failure]. Zaporozhzhye medical journal, 6 (81), 58–62.
Rundneva, E. A. (2008). Nadlezhashaia klinicheskaia praktika I issledovatel. Obshie princypy GCP ICH [Good clinical practice and the researcher. General principles of ICH GCP]. Ukr. med. chasopys, 1 (63), 49–56.
Rebrova, О. Yu. (2002). Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh prohram STATISTICA [Statistical analysis of medical data. Application of software package STATISTICA]. Moscow: Media Sfera, 312.
Anand, I. S. (2008). Heart failure and anemia: mechanisms and pathophysiology Heart Failure Reviews, 13 (4), 379–386. doi: 10.1007/s10741-008-9088-8
Androne, A.-S. (2003). Hemodilution Is Common in Patients With Advanced Heart Failure. Circulation, 107 (2), 226–229. doi: 10.1161/01.cir.0000052623.16194.80
Horwich, T. B., Kalantar-Zadeh, K., MacLellan, R. W., Fonarow, G. C. (2008). Albumin levels predict survival in patients with systolic heart failure. American Heart Journal, 155 (5), 883–889. doi: 10.1016/j.ahj.2007.11.043
Samsky, M. D., Patel, C. B., DeWald, T. A., Smith, A. D., Felker, G. M., Rogers, J. G., Hernandez, A. F. (2013). Cardiohepatic Interactions in Heart Failure. Journal of the American College of Cardiology, 61 (24), 2397–2405. doi: 10.1016/j.jacc.2013.03.042
Téléchargements
Publié-e
Numéro
Rubrique
Licence
(c) Tous droits réservés Петр Петрович Бидзиля 2016
Cette œuvre est sous licence Creative Commons Attribution 4.0 International.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
